Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F.
Taira N, et al. Among authors: kato h.
Breast Cancer. 2022 Jan;29(1):186-188. doi: 10.1007/s12282-021-01296-z.
Breast Cancer. 2022.
PMID: 34562260
Free PMC article.
No abstract available.